



# **PRECIS-2: a tool to improve the applicability of randomised controlled trials**

**Shaun Treweek\***  
[streweek@mac.com](mailto:streweek@mac.com)

**Kirsty Loudon, Frank Sullivan, Merrick Zwarenstein**

**\*Health Services Research Unit  
University of Aberdeen**



---

**HSRU is funded by the Chief Scientist Office of the Scottish Government Health and Social Care Directorates. The author accepts full responsibility for this talk.**

# PRECIS, something to help trialists think through their decision decisions



Journal of Clinical Epidemiology 62 (2009) 464–475

Journal of  
Clinical  
Epidemiology

## ORIGINAL ARTICLE

### A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers

Kevin E. Thorpe<sup>a,\*</sup>, Merrick Zwarenstein<sup>b</sup>, Andrew D. Oxman<sup>c</sup>, Shaun Treweek<sup>d</sup>,  
Curt D. Furberg<sup>e</sup>, Douglas G. Altman<sup>f</sup>, Sean Tunis<sup>g</sup>, Eduardo Bergel<sup>h</sup>, Ian Harvey<sup>i</sup>,  
David J. Magid<sup>j</sup>, Kalipso Chalkidou<sup>k</sup>

<sup>a</sup>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada M5T 3M7

<sup>b</sup>Centre for Health Services Sciences, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre; Institute for Clinical Evaluative Sciences;  
Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada

<sup>c</sup>Preventive and International Health Care Unit, Norwegian Knowledge Centre for the Health Services, Oslo, Norway

<sup>d</sup>Division of Clinical & Population Sciences and Education, University of Dundee, Dundee, UK; Norwegian Knowledge Centre for the  
Health Services, Oslo, Norway

<sup>e</sup>Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA

<sup>f</sup>Centre for Statistics in Medicine, University of Oxford, Oxford, UK

<sup>g</sup>Center for Medical Technology Policy, Baltimore, MD, USA

<sup>h</sup>UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of  
Reproductive Health and Research, World Health Organization, Geneva, Switzerland

<sup>i</sup>Faculty of Health, University of East Anglia, Norwich, UK

<sup>j</sup>Institute for Health Research, Kaiser Permanente Colorado; Departments of Preventive Medicine and Biometrics and Emergency Medicine,  
University of Colorado Health Sciences Center, Denver, CO, USA

<sup>k</sup>National Institute for Health and Clinical Excellence, London, UK

Accepted 13 December 2008

## Abstract

**Objective:** To propose a tool to assist trialists in making design decisions that are consistent with their trial's stated purpose.

**Study Design and Setting:** Randomized trials have been broadly categorized as either having a pragmatic or explanatory attitude. Pragmatic trials seek to answer the question, "Does this intervention work under usual conditions?," whereas explanatory trials are focused on the question, "Can this intervention work under ideal conditions?" Design decisions make a trial more (or less) pragmatic or explanatory, but no tool currently exists to help researchers make the best decisions possible in accordance with their trial's primary goal. During the course of two international meetings, participants with experience in clinical care, research commissioning, health care financing, trial methodology, and reporting defined and refined aspects of trial design that distinguish pragmatic attitudes from explanatory.

**Results:** We have developed a tool (called PRECIS) with 10 key domains and which identifies criteria to help researchers determine how pragmatic or explanatory their trial is. The assessment is summarized graphically.

**Conclusion:** We believe that PRECIS is a useful first step toward a tool that can help trialists to ensure that their design decisions are consistent with the stated purpose of the trial. © 2009 The Authors. Published by Elsevier Inc. All rights reserved.

# PRECIS, something to help trialists think through their decision decisions



ELSEVIER

## A pragmatic—explanatory

Kevin E. Thorpe<sup>a,\*</sup>, Meera K. Jha<sup>b</sup>,  
Curt D. Furberg<sup>c</sup>, Douglas G. Altman<sup>d</sup>

<sup>a</sup>Dalla Lana School of Public Health

<sup>b</sup>Centre for Health Services Sciences, Sunnybrook Health Sciences Centre

<sup>c</sup>Department of Health Policy, Management and Law

<sup>d</sup>Preventive and International Health

<sup>e</sup>Division of Clinical & Population Sciences

<sup>f</sup>Division of Public Health

<sup>g</sup>Centre for Global Health

<sup>h</sup>UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Training on Reproductive Health

<sup>i</sup>Reproductive Health and Research

<sup>j</sup>Institute for Health Research, Kaiser Permanente

<sup>k</sup>University of California

<sup>l</sup>National Institutes of Health


### Abstract

**Objective:** To propose a tool to assist trialists in thinking through their decision decisions.

**Study Design and Setting:** Randomized controlled trials seek to answer the question, “Does this intervention work?” but the question, “Can this intervention work under these conditions?” is often unanswered. However, no tool currently exists to help researchers think through their decision decisions. In the course of two international meetings, participants discussed methodology, and reporting defined and related to pragmatic and explanatory trials.

**Results:** We have developed a tool (called PRECIS) to help trialists think through their decision decisions. It is a tool to help trialists think through their decision decisions.

**Conclusion:** We believe that PRECIS is a tool to help trialists think through their decision decisions. It is consistent with the stated purpose of the tool.



# Developing PRECIS-2: three phases

---

- **Phase 1: brainstorming and a two-round modified Delphi survey of authors who cited PRECIS.**
- **Phase 2: take these results and user test alternative versions of PRECIS-2.**
- **Phase 3: evaluate the validity and reliability of the most promising PRECIS-2 candidate using a sample of 15-20 trials rated by 15 other trialists.**

# Brainstorming

---

- **Add a scoring system?**
- **Better guidance**
- **Drop the analysis domain?**
- **Do we need to weight domains?**
- **Inter-rater reliability a problem?**
- **Is the wheel the best presentation?**




# Delphi Round 1

---

- **Invite authors of papers citing PRECIS to participate (90 - 34 responded).**
- **Ask general questions linked to our brainstorming ideas and questions.**
- **Also asked if people would like to help with Round 2 (23 said Yes)**


# Delphi Round 1 (answering 'yes')

---



# Delphi Round 2 (answering 'yes')

---





# Delphi 2: suggestions for extra domains

---

- **Source of patients or setting for recruitment (x12)**
- **Main objective of trial (x6)**
- **Budget/costs (x6)**
- **Integration with the health care system (x5)**
- **Availability of the drug (x3)**
- **Feasibility of blinding (x5)**
- **Risks (x4)**
- **Appropriateness of methodology/rationale (x3)**

# Ten domains to user-test (first 5)

---


- **Eligibility** - who gets into the trial?
- **Recruitment** - how do participants get into the trial?
- **Setting** - where is the trial being done?
- **Organisation** - what is needed to deliver the intervention?
- **Organisation** - what is needed to deliver the comparator?

# Ten domains to user-test (last 5)

---

- **Flexibility** - how can the intervention be delivered?
- **Flexibility** - how can the comparator be delivered?
- **Follow-up** - how closely are participants followed-up?
- **Primary outcome** - is it directly relevant to participants?
- **Analysis** - are all participants included?

# Abdominal massage in MS patients



# Conclusions

---

- **The original PRECIS tool is widely cited and generally liked but some weaknesses have been highlighted.**
- **Our brainstorming and Delphi generated some concrete suggestions for changes.**
- **Our user-testing will tell us whether these changes are improvements or just changes.**
- **If we get the thumbs-up, we'll go to formal validity and reliability testing.**

# Thank you!

---

[streweek@mac.com](mailto:streweek@mac.com)